<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=windows-1253">
<style type="text/css" style="display:none;"> P {margin-top:0;margin-bottom:0;} </style>
</head>
<body dir="ltr">
<div style="font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 12pt; color: rgb(0, 0, 0);">
<br>
</div>
<div id="Signature">
<div>
<div>
<div class="WordSection1">
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;text-align:center; text-indent:0in; line-height:115%">
<b><span style="font-size:14.0pt; line-height:115%">NAME:</span></b><span style="font-size:14.0pt; line-height:115%"> Xingyue An</span></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-left:.25in; text-align:center; text-indent:0in; line-height:115%">
<span style="font-size:14.0pt; line-height:115%"> </span></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-left:.25in; text-align:center; text-indent:0in; line-height:115%">
<b><span style="font-size:14.0pt; line-height:115%">DATE:</span></b><span style="font-size:14.0pt; line-height:115%"> Wednesday, June 12, 2019<b>
</b></span></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-left:.25in; text-align:center; text-indent:0in; line-height:115%">
<span style="font-size:14.0pt; line-height:115%"> </span></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-left:.25in; text-align:center; text-indent:0in; line-height:115%">
<b><span style="font-size:14.0pt; line-height:115%">TIME: </span></b><span style="font-size:14.0pt; line-height:115%">10:00 AM</span></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-left:.25in; text-align:center; text-indent:0in; line-height:115%">
<span style="font-size:14.0pt; line-height:115%"> </span></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-left:.25in; text-align:center; text-indent:0in; line-height:115%">
<b><span style="font-size:14.0pt; line-height:115%">PLACE:</span></b><span style="font-size:14.0pt; line-height:115%"> Eng. Building 1, Mechanical Engineering Large Conference Room</span></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-left:.25in; text-align:center; text-indent:0in; line-height:115%">
<span style="font-size:14.0pt; line-height:115%"> </span></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-left:.25in; text-align:center; text-indent:0in; line-height:115%">
<b><span style="font-size:14.0pt; line-height:115%">CHAIR/ADVISOR:</span></b><span style="font-size:14.0pt; line-height:115%"> Dr. Navin Varadarajan</span></p>
<div class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;text-align:center; line-height:115%">
<span style="font-size:14.0pt; line-height:115%">
<hr size="2" width="100%" align="center">
</span></div>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;text-align:center; line-height:115%">
<b><span style="font-size:14.0pt; line-height:115%">TITLE:</span></b></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;text-align:center; line-height:115%">
<b><span style="font-size:14.0pt; line-height:115%"> </span></b></p>
<p class="MsoNormal" align="center" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;text-align:center; line-height:115%">
<b><span style="font-size:14.0pt; line-height:115%">Single-cell functional profiling of lymphocytes for cancer immunotherapy</span></b></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;margin-bottom:6.0pt; line-height:115%">
<b> </b></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;line-height:150%">
Immunotherapy by harnessing patients’ the immune system has changed the landscape of cancer therapeutics and shown promising and remarkable clinical responses. However, not all the patients would be beneficial from the treatment. Lymphocytes are a significant
target in anti-tumor immunotherapy, and the functional assessment of lymphocytes will provide insights on their functional biology and will provide a direct path to the improvement of the treatment efficacy.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;line-height:150%">
In the first part of this dissertation, we developed and implemented a methodology based on Timelapse Imaging Microscopy in Nanowell Grids (TIMING) platform that integrates phenotypic profiling and dynamic cytokine secretion with single-cell resolution. Analysis
of hundreds of human peripheral nature killer cells (NK cells) suggested that CD56<sup>dim</sup>CD16<sup>+</sup> NK cells are immediate interferon gamma (IFN-ã) secretor upon activation by phorbol 12-myristate 13-acetate (PMA) and ionomycin (< 3 h), and no
evidence of cooperation between NK cells to synergistic activation or faster IFN-ã secretion. These results establish our technology as an investigational tool for cellular phenotyping and real-time protein secretion of individual cells in a high-throughput
manner and demonstrate that the conventional phenotypic based functional annotation of NK cells might be overly simplistic.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.5in; line-height: 200%; font-size: 12pt; font-family: "Times New Roman", serif;line-height:150%">
In the second part of this dissertation, we performed whole transcriptomic profiling on T cells from acute myeloid leukemia patients (responders and non-responders) who were treated with combination therapy of a hypomethylating agent (5-azacytidine) and an
immune checkpoint inhibitor (Nivolumab, programmed cell death protein 1/PD-1 inhibitor). Sixty-four patient-derived T cells from peripheral blood or bone marrow (site of disease), which were collected before the initiation of the therapy (baseline, T0) and
after the first round of treatment (end of cycle one, EC1), were evaluated. Our results demonstrate (1) treatment-induced gene expression changes on circulating CD8 T cells; (2) bone marrow-derived CD8 T cells consist of higher frequency of effector phenotype;
and (3) the ratios of exhausted and effector T cells, sampled in the periphery, can serve as a biomarker for patient stratification.</p>
</div>
</div>
</div>
</div>
</body>
</html>